Literature DB >> 30713046

Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.

Robert A Kyle1, Dirk R Larson2, Paul J Kurtin3, Shaji Kumar4, James R Cerhan5, Terry M Therneau2, S Vincent Rajkumar4, Celine M Vachon5, Angela Dispenzieri4.   

Abstract

OBJECTIVE: To determine the incidence of immunoglobulin light chain amyloidosis (AL amyloidosis) in a strictly defined geographic area from 1990 through 2015. PATIENTS AND METHODS: We searched a computerized database for the records of all Olmsted County, Minnesota, residents with a diagnosis of AL amyloidosis from January 1, 1990, through December 31, 2015. In addition, records of all residents with a mention of amyloidosis were obtained from the Rochester Epidemiology Project, which contains the medical records of Mayo Clinic and Olmsted Medical Group. The diagnosis of AL amyloidosis was determined by mass spectrometry, immunohistochemical analysis, or positive Congo red staining.
RESULTS: Thirty-five patients were identified as having AL amyloidosis. The median age at diagnosis was 76 years (range, 38-90 years), with men accounting for 54%. The incidence rate of AL amyloidosis from 1990 through 2015 adjusted for age and sex was 1.2 per 100,000 person-years (95% CI, 0.8-1.6 per 100,000 person-years). Rates were similar across the decades 1990-1999, 2000-2009, and 2010-2015 at 1.1, 0.9, and 1.6 per 100,000 person-years, respectively, with no suggestion of an increasing rate during the 26 years. There was a trend toward an increasing incidence over time from 1950 through 2015 in Olmsted County, but it was not significant (P=.15). Applying the rate of 1.2 per 100,000 person-years to the US population of 321 million in 2015, one would expect 3852 new cases of AL amyloidosis in the United States each year.
CONCLUSION: The incidence of AL amyloidosis in Olmsted County has not changed significantly in the past 66 years.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30713046      PMCID: PMC6401262          DOI: 10.1016/j.mayocp.2018.08.041

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  15 in total

1.  "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases.

Authors:  R A KYLE; E D BAYRD
Journal:  Arch Intern Med       Date:  1961-03

2.  Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.

Authors:  Jean D Sipe; Merrill D Benson; Joel N Buxbaum; Shu-Ichi Ikeda; Giampaolo Merlini; Maria J M Saraiva; Per Westermark
Journal:  Amyloid       Date:  2016-11-24       Impact factor: 7.141

3.  Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

4.  Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.

Authors:  Julie A Vrana; Jason D Theis; Surendra Dasari; Oana M Mereuta; Angela Dispenzieri; Steven R Zeldenrust; Morie A Gertz; Paul J Kurtin; Karen L Grogg; Ahmet Dogan
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

5.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program.

Authors:  P H Levine; S C Steinhorn; L G Ries; J L Aron
Journal:  J Natl Cancer Inst       Date:  1985-02       Impact factor: 13.506

6.  Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Authors:  Julie A Vrana; Jeffrey D Gamez; Benjamin J Madden; Jason D Theis; H Robert Bergen; Ahmet Dogan
Journal:  Blood       Date:  2009-10-01       Impact factor: 22.113

Review 7.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

Review 8.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.

Authors:  Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2012-11-28       Impact factor: 7.616

9.  Epidemiology of AL amyloidosis: a real-world study using US claims data.

Authors:  Tiffany P Quock; Tingjian Yan; Eunice Chang; Spencer Guthrie; Michael S Broder
Journal:  Blood Adv       Date:  2018-05-22

10.  Incidence and survival in non-hereditary amyloidosis in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  BMC Public Health       Date:  2012-11-13       Impact factor: 3.295

View more
  22 in total

Review 1.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

Review 2.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.

Authors:  Giuliana G Repetti; Christopher N Toepfer; Jonathan G Seidman; Christine E Seidman
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 3.  Cardiac Amyloidosis.

Authors:  Morie A Gertz
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

Review 4.  Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.

Authors:  Jin Chul Paeng; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

5.  Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Authors:  Vikram J Premkumar; Suzanne Lentzsch; Samuel Pan; Divaya Bhutani; Joshua Richter; Sundar Jagannath; Michaela Liedtke; Arnaud Jaccard; Ashutosh D Wechalekar; Raymond Comenzo; Vaishali Sanchorawala; Bruno Royer; Michael Rosenzweig; Jason Valent; Stefan Schönland; Rafael Fonseca; Sandy Wong; Prashant Kapoor
Journal:  Blood Cancer J       Date:  2021-01-11       Impact factor: 11.037

6.  Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients.

Authors:  Alissa Visram; Abdullah S Al Saleh; Harsh Parmar; Jennifer S McDonald; John C Lieske; Iuliana Vaxman; Eli Muchtar; Miriam Hobbs; Amie Fonder; Yi L Hwa; Francis K Buadi; David Dingli; Martha Q Lacy; Angela Dispenzieri; Prashant Kapoor; Suzanne R Hayman; Rahma Warsame; Taxiarchis V Kourelis; Mustaqeem Siddiqui; Wilson I Gonsalves; John A Lust; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz; Shaji K Kumar; Nelson Leung
Journal:  Blood Cancer J       Date:  2020-12-11       Impact factor: 11.037

Review 7.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

8.  Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.

Authors:  Andrew Staron; Lawreen H Connors; Luke Zheng; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2020-11-10       Impact factor: 11.037

Review 9.  The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.

Authors:  Isabelle Lousada
Journal:  Orphanet J Rare Dis       Date:  2020-09-29       Impact factor: 4.123

10.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.